Exact Mass: 422.163

Exact Mass Matches: 422.163

Found 47 metabolites which its exact mass value is equals to given mass value 422.163, within given mass tolerance error 0.001 dalton. Try search metabolite list with more accurate mass tolerance error 0.0002 dalton.

Losartan

[2-butyl-4-chloro-1-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1H-imidazol-5-yl]methanol

C22H23ClN6O (422.1622)


Losartan is an angiotensin-receptor blocker (ARB) that may be used alone or with other agents to treat hypertension. Losartan and its longer acting metabolite, E-3174, lower blood pressure by antagonizing the renin-angiotensin-aldosterone system (RAAS); they compete with angiotensin II for binding to the type-1 angiotensin II receptor (AT1) subtype and prevents the blood pressure increasing effects of angiotensin II. Unlike angiotensin-converting enzyme (ACE) inhibitors, ARBs do not have the adverse effect of dry cough. Losartan may be used to treat hypertension, isolated systolic hypertension, left ventricular hypertrophy and diabetic nephropathy. It may also be used as an alternative agent for the treatment of systolic dysfunction, myocardial infarction, coronary artery disease, and heart failure. C - Cardiovascular system > C09 - Agents acting on the renin-angiotensin system > C09C - Angiotensin ii receptor blockers (arbs), plain > C09CA - Angiotensin ii receptor blockers (arbs), plain C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C66930 - Angiotensin II Receptor Antagonist COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials, COVID-19 Disease Map D057911 - Angiotensin Receptor Antagonists > D047228 - Angiotensin II Type 1 Receptor Blockers D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents CONFIDENCE standard compound; EAWAG_UCHEM_ID 2794 CONFIDENCE standard compound; INTERNAL_ID 8189 CONFIDENCE standard compound; INTERNAL_ID 8607 CONFIDENCE standard compound; INTERNAL_ID 2280 Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS Losartan is an angiotensin II receptor antagonist, competing with the binding of angiotensin II to AT1 receptors with IC50 of 20 nM.

   
   
   
   
   

losartan

losartan

C22H23ClN6O (422.1622)


C - Cardiovascular system > C09 - Agents acting on the renin-angiotensin system > C09C - Angiotensin ii receptor blockers (arbs), plain > C09CA - Angiotensin ii receptor blockers (arbs), plain C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C66930 - Angiotensin II Receptor Antagonist COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials, COVID-19 Disease Map D057911 - Angiotensin Receptor Antagonists > D047228 - Angiotensin II Type 1 Receptor Blockers D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS Losartan is an angiotensin II receptor antagonist, competing with the binding of angiotensin II to AT1 receptors with IC50 of 20 nM.

   

Cys Phe Gly Pro

(2S)-1-{2-[(2S)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-phenylpropanamido]acetyl}pyrrolidine-2-carboxylic acid

C19H26N4O5S (422.1624)


   

Cys Phe Pro Gly

2-{[(2S)-1-[(2S)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-phenylpropanoyl]pyrrolidin-2-yl]formamido}acetic acid

C19H26N4O5S (422.1624)


   

Cys Gly Phe Pro

(2S)-1-[(2S)-2-{2-[(2R)-2-amino-3-sulfanylpropanamido]acetamido}-3-phenylpropanoyl]pyrrolidine-2-carboxylic acid

C19H26N4O5S (422.1624)


   

Cys Gly Pro Phe

(2S)-2-{[(2S)-1-{2-[(2R)-2-amino-3-sulfanylpropanamido]acetyl}pyrrolidin-2-yl]formamido}-3-phenylpropanoic acid

C19H26N4O5S (422.1624)


   

Cys Pro Phe Gly

2-[(2S)-2-{[(2S)-1-[(2R)-2-amino-3-sulfanylpropanoyl]pyrrolidin-2-yl]formamido}-3-phenylpropanamido]acetic acid

C19H26N4O5S (422.1624)


   

Cys Pro Gly Phe

(2S)-2-(2-{[(2S)-1-[(2R)-2-amino-3-sulfanylpropanoyl]pyrrolidin-2-yl]formamido}acetamido)-3-phenylpropanoic acid

C19H26N4O5S (422.1624)


   

Phe Cys Gly Pro

(2S)-1-{2-[(2R)-2-[(2S)-2-amino-3-phenylpropanamido]-3-sulfanylpropanamido]acetyl}pyrrolidine-2-carboxylic acid

C19H26N4O5S (422.1624)


   

Phe Cys Pro Gly

2-{[(2S)-1-[(2R)-2-[(2S)-2-amino-3-phenylpropanamido]-3-sulfanylpropanoyl]pyrrolidin-2-yl]formamido}acetic acid

C19H26N4O5S (422.1624)


   

Phe Gly Cys Pro

(2S)-1-[(2R)-2-{2-[(2S)-2-amino-3-phenylpropanamido]acetamido}-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid

C19H26N4O5S (422.1624)


   

Phe Gly Pro Cys

(2R)-2-{[(2S)-1-{2-[(2S)-2-amino-3-phenylpropanamido]acetyl}pyrrolidin-2-yl]formamido}-3-sulfanylpropanoic acid

C19H26N4O5S (422.1624)


   

Phe Pro Cys Gly

2-[(2R)-2-{[(2S)-1-[(2S)-2-amino-3-phenylpropanoyl]pyrrolidin-2-yl]formamido}-3-sulfanylpropanamido]acetic acid

C19H26N4O5S (422.1624)


   

Phe Pro Gly Cys

(2R)-2-(2-{[(2S)-1-[(2S)-2-amino-3-phenylpropanoyl]pyrrolidin-2-yl]formamido}acetamido)-3-sulfanylpropanoic acid

C19H26N4O5S (422.1624)


   

Gly Cys Phe Pro

(2S)-1-[(2S)-2-[(2R)-2-(2-aminoacetamido)-3-sulfanylpropanamido]-3-phenylpropanoyl]pyrrolidine-2-carboxylic acid

C19H26N4O5S (422.1624)


   

Gly Cys Pro Phe

(2S)-2-{[(2S)-1-[(2R)-2-(2-aminoacetamido)-3-sulfanylpropanoyl]pyrrolidin-2-yl]formamido}-3-phenylpropanoic acid

C19H26N4O5S (422.1624)


   

Gly Phe Cys Pro

(2S)-1-[(2R)-2-[(2S)-2-(2-aminoacetamido)-3-phenylpropanamido]-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid

C19H26N4O5S (422.1624)


   

Gly Phe Pro Cys

(2R)-2-{[(2S)-1-[(2S)-2-(2-aminoacetamido)-3-phenylpropanoyl]pyrrolidin-2-yl]formamido}-3-sulfanylpropanoic acid

C19H26N4O5S (422.1624)


   

Gly Pro Cys Phe

(2S)-2-[(2R)-2-{[(2S)-1-(2-aminoacetyl)pyrrolidin-2-yl]formamido}-3-sulfanylpropanamido]-3-phenylpropanoic acid

C19H26N4O5S (422.1624)


   

Gly Pro Phe Cys

(2R)-2-[(2S)-2-{[(2S)-1-(2-aminoacetyl)pyrrolidin-2-yl]formamido}-3-phenylpropanamido]-3-sulfanylpropanoic acid

C19H26N4O5S (422.1624)


   
   
   

Pro Cys Phe Gly

2-[(2S)-3-phenyl-2-[(2R)-2-[(2S)-pyrrolidin-2-ylformamido]-3-sulfanylpropanamido]propanamido]acetic acid

C19H26N4O5S (422.1624)


   

Pro Cys Gly Phe

(2S)-3-phenyl-2-{2-[(2R)-2-[(2S)-pyrrolidin-2-ylformamido]-3-sulfanylpropanamido]acetamido}propanoic acid

C19H26N4O5S (422.1624)


   

Pro Phe Cys Gly

2-[(2R)-2-[(2S)-3-phenyl-2-[(2S)-pyrrolidin-2-ylformamido]propanamido]-3-sulfanylpropanamido]acetic acid

C19H26N4O5S (422.1624)


   

Pro Phe Gly Cys

(2R)-2-{2-[(2S)-3-phenyl-2-[(2S)-pyrrolidin-2-ylformamido]propanamido]acetamido}-3-sulfanylpropanoic acid

C19H26N4O5S (422.1624)


   

Pro Gly Cys Phe

(2S)-3-phenyl-2-[(2R)-2-{2-[(2S)-pyrrolidin-2-ylformamido]acetamido}-3-sulfanylpropanamido]propanoic acid

C19H26N4O5S (422.1624)


   

Pro Gly Phe Cys

(2R)-2-[(2S)-3-phenyl-2-{2-[(2S)-pyrrolidin-2-ylformamido]acetamido}propanamido]-3-sulfanylpropanoic acid

C19H26N4O5S (422.1624)


   
   
   
   
   

[2-butyl-5-chloro-1-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol

[2-butyl-5-chloro-1-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol

C22H23ClN6O (422.1622)


   

3-[5-(3-METHYL-5-ISOXAZOLYL)-2-(METHYLSULFONYL)-4-PYRIMIDINYL]-1-PIPERIDINECARBOXYLIC ACID,1,1-DIMETHYLETHYL ESTER

3-[5-(3-METHYL-5-ISOXAZOLYL)-2-(METHYLSULFONYL)-4-PYRIMIDINYL]-1-PIPERIDINECARBOXYLIC ACID,1,1-DIMETHYLETHYL ESTER

C19H26N4O5S (422.1624)


   

Btk inhibitor 1 (R enantiomer hydrochloride)

Btk inhibitor 1 (R enantiomer hydrochloride)

C22H23ClN6O (422.1622)


   

3-[[1-(dimethylsulfamoyl)-4-piperidinyl]oxy]-N-[(3-methyl-5-isoxazolyl)methyl]benzamide

3-[[1-(dimethylsulfamoyl)-4-piperidinyl]oxy]-N-[(3-methyl-5-isoxazolyl)methyl]benzamide

C19H26N4O5S (422.1624)


   
   
   
   
   
   
   

4-hydroxy-3,6-bis(1h-indol-3-yl)-5-(3-methylbut-2-en-1-yl)cyclohexa-3,5-diene-1,2-dione

4-hydroxy-3,6-bis(1h-indol-3-yl)-5-(3-methylbut-2-en-1-yl)cyclohexa-3,5-diene-1,2-dione

C27H22N2O3 (422.163)